RxLedger

Cyclosporine* (Cyclosporine) — Medicare Part D spending

Multiple manufacturers (6) · Rank #189 by total Part D spend · CMS data year 2023

Medicare Part D spent $255,901,494 on Cyclosporine* (Cyclosporine) in 2023, the #189 drug by total Part D spending out of 3,598 drugs. That worked out to about $5.66 per dosage unit, $542 per claim and $1,356 per beneficiary, across 472,423 claims for 188,711 beneficiaries. Average spending per dosage unit fell -14.4% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Cyclosporine* (Cyclosporine) spending at a glance (2023)

MetricCyclosporine* (Cyclosporine)
Total Part D spending (2023)$255,901,494
Total spending (2022)$112,994,238
Year-over-year change in total spending+126.5%
Average spending per dosage unit (2023)$5.66
Change in spend per dosage unit (YoY)-14.4%
Avg annual change per dosage unit (2019-2023 CAGR)-0.7%
Average spending per claim (2023)$542
Average spending per beneficiary (2023)$1,356
Total claims (2023)472,423
Beneficiaries (2023)188,711
Total dosage units (2023)45,429,930
Manufacturer(s)Multiple manufacturers (6)
National rank by total spend (of 3,598 drugs)#189

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

2022 vs 2023

Cyclosporine* (Cyclosporine): year-over-year Medicare Part D figures. Per-claim/per-beneficiary "change" omitted because it mixes price and utilization. Source: CMS Medicare Part D Spending by Drug (data year 2023).
Metric20222023Change
Total spending$112,994,238$255,901,494+126.5%
Avg spend per dosage unit$6.61$5.66-14.4%
Avg spend per claim$601$542
Avg spend per beneficiary$1,169$1,356
Total claims188,162472,423
Beneficiaries96,639188,711

How Cyclosporine* compares with nearby drugs

Drugs with total Part D spending closest to Cyclosporine* (Cyclosporine):

Cyclosporine* (Cyclosporine) and its nearest-spend peers. Source: CMS Medicare Part D Spending by Drug (data year 2023), data year 2023.
Drug (rank)Total spend 2023Per dosage unitPer-unit YoY
Cyclosporine* (Cyclosporine) (this drug, #189)$255,901,494$5.66-14.4%
Strensiq (Asfotase Alfa) (#187)$258,940,106$6,180.92-0.9%
Humira (Adalimumab) (#188)$257,644,313$3,568.20+11.4%
Xolair (Omalizumab) (#190)$254,056,609$1,363.73+7.7%
Xtampza ER (Oxycodone Myristate) (#191)$250,042,795$11.75+4.8%
Metformin HCl (#192)$247,531,906$0.0723+26.7%

Frequently asked questions

How much does Medicare Part D spend on Cyclosporine*?

Medicare Part D spent $255,901,494 on Cyclosporine* (Cyclosporine) in 2023 (the latest CMS data year), across 472,423 claims for 188,711 beneficiaries. That ranks #189 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.

What is the average spending per dosage unit for Cyclosporine*?

In 2023, the weighted average Medicare Part D spending per dosage unit for Cyclosporine* (Cyclosporine) was $5.66. Compared with 2022 it fell -14.4%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.

Who makes Cyclosporine*?

CMS attributes Cyclosporine* (Cyclosporine) to Multiple manufacturers (6) in the 2023 Part D spending file. Average spending per claim was $542 and per beneficiary $1,356.

Is the Cyclosporine* figure the price I pay?

No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.

Keep exploring

Source & what this means

Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-20